Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 770 participants.

Also called NCT03351478

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 770 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03351478
  • EudraCT 2016-001803-22
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, Canada, Czechia, France, Italy, Latvia, Mexico, Russia, Slovakia, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03351478. Randomized; double masking; primary purpose treatment. Start 2017-11-27 (actual); primary completion 2019-05-16 (actual). Results posted on 2021-05-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
Acronym
SOTA-EMPA
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sotagliflozin
Intervention (Drug)
Empagliflozin
Intervention (Drug)
Placebo
Intervention (Drug)
Placebo
Lead sponsor
Lexicon Pharmaceuticals (class: industry)
Collaborator
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct03351478
Content hash
338de4d0fbbf72842f7a61bcfefeb30e65238b5dc08c4614d26be2356c3da002